Anzeige
Mehr »
Mittwoch, 08.04.2026 - Börsentäglich über 12.000 News
Oregen Energy baut Position aus - während Öl bei $96 konsolidiert und Namibias Mega-Ölboom weiter eskaliert
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Zacks

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DiDon't Overlook These Highly Ranked Dividend Stocks: LCUT, KRT, MGA, SFD
DiMicron and Broadcom: 2 Critical AI Infrastructure Enablers
DiBroadcom Slips 9% - Why Smart Investors Should Buy the Dip Now
Di3 Best Earnings Acceleration Stocks to Buy Now for April 2026
DiVenture Global Gains From Strong LNG Demand and Contract Visibility
DiWeRide Expands Robotaxi Push Across Singapore and Dubai
DiRivian Beats on Q1 Delivery Estimates Ahead of R2 Launch
DiHere's Why Investors Should Stay Neutral on Unum Group for Now
DiEQNR Awards Reach Subsea for Development of NCS Using Reach Remote 1
DiSTXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery
DiDenali Stock Falls as Partner Takeda Ends Collaboration Deal
DiDraganfly Stock Surges 147.6% in a Year: Time to Hold or Book Profits?
DiWhat's Driving Tempus AI Data and Applications Arm's Robust Growth?
Di5 Low-Leverage Stocks to Buy as Investors Hope for Truce
DiSHOP Rides on Robust Merchant Solutions Revenues: More Upside Ahead?
DiQuantum IPO Pipeline Reopens: 1 Pure Play and 2 Enablers Stand Out
DiAre Low Margins Hurting Gold.com Despite Its Strong Revenue Base?
DiAlto Ingredients: From Losses to Gradual Margin Recovery?
DiShould You Buy SoFi Technologies Stock After a YTD Decline of 38%?
DiRS: Spot Tomorrow's Leaders in Today's Volatility
DiKey Reasons to Add Crown Castle Stock to Your Portfolio Now
DiOccidental Outperforms Industry in the Past Year: Time to Buy or Wait?
DiHercules Capital's Q1 New Commitments Reach Record $1.81 Billion
DiAre Rising Earnings Estimates a Solid Reason to Bet on HUBS Stock?
DiSNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema